Morphological basis of Parkinson disease-associated cognitive impairment: an update
- 20 June 2022
- journal article
- review article
- Published by Springer Nature in Journal of Neural Transmission
- Vol. 129 (8) , 977-999
Abstract
Cognitive impairment is one of the most salient non-motor symptoms of Parkinson disease (PD) that poses a significant burden on the patients and carers as well as being a risk factor for early mortality. People with PD show a wide spectrum of cognitive dysfunctions ranging from subjective cognitive decline and mild cognitive impairment (MCI) to frank dementia. The mean frequency of PD with MCI (PD-MCI) is 25.8% and the pooled dementia frequency is 26.3% increasing up to 83% 20 years after diagnosis. A better understanding of the underlying pathological processes will aid in directing disease-specific treatment. Modern neuroimaging studies revealed considerable changes in gray and white matter in PD patients with cognitive impairment, cortical atrophy, hypometabolism, dopamine/cholinergic or other neurotransmitter dysfunction and increased amyloid burden, but multiple mechanism are likely involved. Combined analysis of imaging and fluid markers is the most promising method for identifying PD-MCI and Parkinson disease dementia (PDD). Morphological substrates are a combination of Lewy- and Alzheimer-associated and other concomitant pathologies with aggregation of α-synuclein, amyloid, tau and other pathological proteins in cortical and subcortical regions causing destruction of essential neuronal networks. Significant pathological heterogeneity within PD-MCI reflects deficits in various cognitive domains. This review highlights the essential neuroimaging data and neuropathological changes in PD with cognitive impairment, the amount and topographical distribution of pathological protein aggregates and their pathophysiological relevance. Large-scale clinicopathological correlative studies are warranted to further elucidate the exact neuropathological correlates of cognitive impairment in PD and related synucleinopathies as a basis for early diagnosis and future disease-modifying therapies.Keywords
This publication has 279 references indexed in Scilit:
- Relationship between cognitive impairment and white-matter alteration in Parkinson’s disease with dementia: tract-based spatial statistics and tract-specific analysisEuropean Radiology, 2013
- Pathologic Accumulation of α-Synuclein and Aβ in Parkinson Disease Patients With DementiaArchives of Neurology, 2012
- Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelinesMovement Disorders, 2012
- Neurodegeneration Across Stages of Cognitive Decline in Parkinson DiseaseArchives of Neurology, 2011
- Amyloid imaging of Lewy body‐associated disordersMovement Disorders, 2010
- Heterogeneous neuropathological findings in Parkinson’s disease with mild cognitive impairmentActa Neuropathologica, 2010
- The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementiaActa Neuropathologica, 2010
- Mild Cognitive ImpairmentArchives of Neurology, 2009
- Low sensitivity in clinical diagnoses of dementia with Lewy bodiesJournal of Neurology, 2009
- Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunctionActa Neuropathologica, 2009